# Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Submission date	Recruitment status	<ul><li>Prospectively registered</li><li>Protocol</li></ul>			
23/06/2008	No longer recruiting				
Registration date	Overall study status	Statistical analysis plan			
11/03/2009	Completed	[X] Results			
Last Edited	Condition category	Individual participant data			
20/03/2020	Nervous System Diseases				

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Genzyme Medical Information Representative

#### Contact details

Genzyme Therapeutics
4620
Kingsgate
Cascade Way
Oxford Business Park South
Oxford
United Kingdom
OX4 2SU
+44 (0)1865 405283
ukmedinfo@genzyme.com

# Additional identifiers

ClinicalTrials.gov (NCT)

NCT00548405

#### Protocol serial number

CAMMS324 A2; NTR1469; ACTRN12608000426381

# Study information

#### Scientific Title

A phase 3 randomised, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon beta-1a (Rebif®) in patients with relapsing-remitting multiple sclerosis who have relapsed on therapy

#### **Acronym**

CARE-MS II

# **Study objectives**

Amended hypothesis as of 24/06/2009:

The purpose of this study is to establish the efficacy and safety of two different doses of alemtuzumab as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with Rebif® (interferon beta-1a). The study will enrol patients who have received an adequate trial of disease-modifying therapies but continued to relapse while being treated, and who meet a minimum severity of disease as measured by magnetic resonance imaging (MRI). Patients will have monthly laboratory tests and comprehensive testing every 3 months. Every patient will receive active treatment; there is no placebo. The 24 mg alemtuzumab dose is closed to enrolment so newly enrolled patients will be randomly assigned to treatment with either 12 mg alemtuzumab or Rebif® at a 2:1 ratio (i.e., 2 given 12 mg alemtuzumab for every 1 given Rebif®). Alemtuzumab will be administered in two annual cycles, once at the beginning of the study and again 1 year later. Rebif® will be self-injected 3 times per week for 2 years. All patients will be required to return to their study site every 3 months for neurological assessment. In addition. safety-related laboratory tests will be performed at least monthly. Participation in this study will end 2 years after the start of treatment for each patient. Additionally, all patients who receive alemtuzumab will be followed in an extension study for safety and efficacy assessments. Patients who receive Rebif® and complete 2 years on study may be eligible to receive alemtuzumab in an extension study.

#### Initial information at time of registration:

The purpose of this study is to establish the efficacy and safety of two different doses of alemtuzumab as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with Rebif® (interferon beta-1a). The study will enrol patients who have received an adequate trial of disease-modifying therapies but continued to relapse while being treated, and who meet a minimum severity of disease as measured by magnetic resonance imaging (MRI). Patients will have monthly blood tests and comprehensive testing every 3 months. Every patient will receive active treatment; there is no placebo. Patients who qualify will be randomly assigned to treatment with either low-dose alemtuzumab, high-dose alemtuzumab, or Rebif® at a 2:2:1 ratio (i.e., there is a 4-in-5 chance patients will be assigned to receive alemtuzumab treatment and a 1in-5 chance patients will be assigned to receive Rebif® treatment). Alemtuzumab will be administered in two annual cycles, once at the beginning of the study and again 1 year later. Rebif® will be self-injected 3 times per week for 2 years. All patients will be required to return to their study site every 3 months for neurological assessment. In addition, a safety-related blood test will be performed at least monthly. Participation in this study will end 2 years after the start of treatment for each patient. Additionally, all patients who receive alemtuzumab will be followed in an extension study for safety for at least 3 years after their last dose of alemtuzumab. Patients who receive Rebif® and complete 2 years on study may be eligible to receive alemtuzumab in an extension study.

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Warwickshire Local Research Ethics Committee (UK), 24/12/2007, ref: 07/H1211/153. All other centres will seek ethics approval before recruiting patients.

# Study design

Randomised parallel-assignment single-blind (outcome assessor) multi-centre trial

# Primary study design

Interventional

# Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Multiple sclerosis

#### **Interventions**

Experimental Intervention 1: alemtuzumab: 12 mg per day administered through IV, once a day for 5 consecutive days at Month 0 and 12 mg per day administered through IV, once a day for 3 consecutive days at Month 12

Experimental Intervention 2: alemtuzumab: 24 mg per day administered through IV, once a day for 5 consecutive days at Month 0 and 24 mg per day administered through IV, once a day for 3 consecutive days at Month 12 (please note that as of 24/06/2009 the 24 mg alemtuzumab dose is closed to enrolment).

Active Comparator: interferon beta-1a (Rebif®): 44 mcg administered 3-times weekly by SC injections for 2 years

Details of Lead Principal Investigator for the UK sites: Dr Alasdair Coles Addenbrooke's Hospital Box 165 Hill's Road Cambridge, CB2 2QQ United Kingdom

# Intervention Type

Drug

#### Phase

Phase III

# Drug/device/biological/vaccine name(s)

Alemtuzumab, interferon beta-1a (Rebif®)

# Primary outcome(s)

- 1. Time to Sustained Accumulation of Disability (SAD) (Time frame: 2 years)
- 2. Relapse Rate (Time frame: 2 years)

# Key secondary outcome(s))

- 1. Proportion of patients who are relapse free at Year 2 (Time frame: 2 years)
- 2. Change from baseline in EDSS (Time frame: 2 years)
- 3. Acquisition of disability as measured by change from baseline in Multiple Sclerosis Functional Composite (MSFC) (Time frame: 2 years)
- 4. Percent change from baseline in MRI-T2 hyperintense lesion volume at Year 2 (Time frame: 2 years)

# Completion date

01/04/2012

# Eligibility

# Key inclusion criteria

Amended as of 24/06/2009:

Point 7 has been removed from the below inclusion criteria.

Initial information at time of registration:

- 1. Males and females, aged 18 55 years old
- 2. Diagnosis of MS and MRI scan demonstrating white matter lesions attributable to MS
- 3. Onset of MS symptoms within 10 years of screening
- 4. Expanded Disability Status Scale (EDSS) score 0.0 to 5.0
- 5. Greater than or equal to 2 MS attacks within 24 months, with greater than or equal to 1 attack within 12 months
- 6. Greater than or equal to 1 MS attack (relapse) during treatment with a beta interferon therapy or glatiramer acetate after being on that therapy for at least 6 months within 10 years
- 7. Neurologically stable for the 30 days prior to the date the Informed Consent Form is signed

# Participant type(s)

Patient

# Healthy volunteers allowed

No

# Age group

Adult

# Lower age limit

18 years

#### Sex

Αll

# Key exclusion criteria

- 1. Previous treatment with alemtuzumab
- 2. Previous treatment with any investigational drug (i.e. medication that is not approved at any

dose for any indication)

- 3. Treatment with natalizumab, methotrexate, azathioprine or cyclosporine in the past 6 months
- 4. Previous treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab, or any other immunosuppressive, or cytotoxic therapy (other than steroid treatment)
- 5. Any progressive form of MS
- 6. Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS
- 7. Major systemic disease that cannot be treated or adequately controlled by therapy
- 8. Active infection, or high risk for infection
- 9. Autoimmune disorder (other than MS)
- 10. Impaired hepatic or renal function
- 11. History of malignancy, except basal skin cell carcinoma
- 12. Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study
- 13. Known bleeding disorder
- 14. Of childbearing potential with a positive serum pregnancy test, pregnant, or lactating
- 15. Current participation in another clinical study or previous participation in CAMMS323 (registered with ISRCTN21534255)
- 16. Previous hypersensitivity reaction to any immunoglobulin product
- 17. Known allergy or intolerance to interferon beta, human albumin, or mannitol
- 18. Intolerance of pulsed corticosteroids, especially a history of steroid psychosis
- 19. Inability to self-administer subcutaneous (SC) injections or receive SC injections from caregiver
- 20. Inability to undergo MRI with gadolinium administration
- 21. Unwilling to use a reliable and acceptable contraceptive method throughout the study period (fertile patients only)

# Date of first enrolment 20/10/2007

Date of final enrolment 02/09/2009

# Locations

Countries	of recruitment
United Kir	ngdom

England

Argentina

Australia

Austria

Belgium

Brazil

Croatia					
Czech Republic					
Denmark					
France					
Germany					
Israel					
Italy					
Mexico					
Netherlands					
Poland					
Russian Federation					
Serbia					
Spain					
Sweden					
Ukraine					
United States of America					
Study participating centre					

Canada

Genzyme Therapeutics
Oxford
United Kingdom
OX4 2SU

# Sponsor information

# ${\bf Organisation}$

Genzyme Corporation (USA)

# **ROR**

https://ror.org/027vj4x92

# Funder(s)

# Funder type

Industry

#### **Funder Name**

Genzyme

# Alternative Name(s)

Genzyme Corporation

# **Funding Body Type**

Private sector organisation

# **Funding Body Subtype**

For-profit companies (industry)

#### Location

United States of America

#### Funder Name

**Bayer Schering** 

# Alternative Name(s)

# **Funding Body Type**

Private sector organisation

# **Funding Body Subtype**

For-profit companies (industry)

#### Location

Germany

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created Da	ate added	Peer reviewed?	Patient-facing?
Results article	results	24/11/2012		Yes	No
Basic results				No	No
Participant information sheet	Participant information sheet	11/11/2025 11	1/11/2025	No	Yes